Cosopt Versus Xalatan

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pharmaceutical Research Network
• Treatments: Dorzolamide; Latanoprost; Maleic acid; Timolol

Criteria

Inclusion Criteria:

• adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular hypertenstion

• intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H

• ETDRS visual acuity must be 1.0 or better in both eyes

Exclusion Criteria:

• any contraindications to study medications

• any anticipated change in systemic hypertensive therapy during the trial